Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.44 AUD | +3.39% | +1.24% | +28.08% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- Analyst opinion has improved significantly over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- The company does not generate enough profits, which is an alarming weak point.
- The company is in debt and has limited leeway for investment
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+28.08% | 379M | B+ | ||
-24.16% | 7.76B | B+ | ||
+68.65% | 4.33B | C+ | ||
-2.98% | 2.64B | - | ||
+2.72% | 2.63B | B- | ||
-46.17% | 2.16B | B- | ||
-22.12% | 1.46B | A- | ||
+13.62% | 1.17B | B+ | ||
-43.81% | 1.14B | C+ | ||
+20.41% | 999M | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- IDX Stock
- Ratings Integral Diagnostics Limited